Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
LG

NASDAQ · LGND

Ligand Pharmaceuticals Incorporated

Healthcare · Biotechnology

$296.94

Down-$9.83 (-3.20%)

Updated Oct 7, 2026, 7:05 AM

SID Score

6.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.6B
P/E ratio
99
Dividend yield
0.00%
52-week range
$175.89 – $326.63
Volume
163.74K
Avg. volume
207.76K

Price performance · LGND

LGND price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

LGND closed at $296.94 after 21 trading sessions, up 2.81% for the selected period.

Last close
$296.94
Period change
+2.81%
Period low
$275.20
Period high
$314.10
Daily close
View OHLC price history
LGND OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$309.41$309.41$293.725$296.94163.74K
Oct 5, 2026$303.95$309.77$300.7851$306.77163.82K
Oct 2, 2026$307.55$307.63$301.32$302.96179.23K
Oct 1, 2026$309.82$312.05$301.48$302.74374.02K
Sep 30, 2026$310.52$317.23$306.95$312.37505.86K
Sep 29, 2026$313.63$317.10$304.355$310.36430.96K
Sep 28, 2026$299.78$314.94$299.70$314.10241.74K
Sep 25, 2026$303.17$305.345$293.90$301.52305.8K
Sep 24, 2026$296.95$303.41$296.37$299.04210.28K
Sep 23, 2026$300.44$302.44$296.08$298.41242.2K
Sep 22, 2026$291.00$300.48$289.00$298.50308.77K
Sep 21, 2026$283.67$290.51$282.45$290.07237.48K
Sep 18, 2026$285.63$285.64$280.49$283.49372.8K
Sep 17, 2026$279.51$285.51$273.102$284.70248.81K
Sep 16, 2026$277.97$278.74$271.215$275.20299.04K
Sep 15, 2026$280.53$280.53$270.77$276.98180.23K
Sep 14, 2026$284.93$287.14$280.12$280.65158.77K
Sep 11, 2026$291.48$294.00$283.77$284.47261.17K
Sep 10, 2026$285.00$291.26$283.04$289.25146.55K
Sep 9, 2026$288.03$291.82$285.48$288.05309.96K
Sep 8, 2026$285.05$289.28$278.3953$288.83216.42K

Latest LGND news

The latest Smart Investors Daily articles mentioning LGND.

Stock researchCompany · Overview

LGND research

Overview

Company profile and research snapshot.

Company profile

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$245.33
Implied upside
—
Analysts
—
LGND recent ratings
DateFirmRatingTarget
Sep 25, 2026BarclaysOverweight—
Sep 24, 2026HC Wainwright & Co.Buy—
Sep 23, 2026CitigroupBuy—
Aug 14, 2026Leerink PartnersOutperform—
Aug 7, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?

Why the AvenCell financing matters for Ligand Pharmaceuticals Ligand Pharmaceuticals (LGND) has agreed to provide up to $47 million in funding to AvenCell Therapeutics, tying most of the capital to clinical milestones in AvenCell’s CAR-T therapy programs. The agreement extends Ligand’s royalty-focused approach, giving the business potential future royalty rights on AvenCell’s existing CAR-T pipeline and any later programs that emerge from the partnership. Recent trading has been strong for...

Yahoo · Sep 29, 2026

Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal

Ligand Pharmaceuticals has delivered a very strong run in recent years, and the question now is whether the cash the business can generate is enough to support where the stock trades today. With a Discounted Cash Flow (DCF) view available, the focus naturally turns to how the current price lines up with the cash flows investors expect the company to produce over time. Over the past 3 years, Ligand Pharmaceuticals has returned about 430.8%, which puts a lot of weight on whether the cash flow...

Yahoo · Sep 29, 2026

Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?

Ligand Pharmaceuticals recently entered a US$47 million financing agreement with AvenCell Therapeutics, including up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell’s CAR-T therapy programs. The deal deepens Ligand’s royalty-focused model by adding potential royalty streams on AvenCell’s current and future pipeline, further broadening its portfolio of over 200 partnered assets following the XOMA Royalty acquisition. We’ll now examine...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By